サンプル依頼リスト カート
  • English
  • Korean
表紙：2型糖尿病の世界市場レポート 2024年
市場調査レポート
商品コード
1415797

2型糖尿病の世界市場レポート 2024年

Type 2 Diabetes Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
2型糖尿病の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

2型糖尿病市場規模は近年力強く成長しています。2023年の445億6,000万米ドルから2024年には481億4,000万米ドルに、CAGR8.0％で拡大します。実績期間の成長は、ライフスタイルや食生活の変化、高齢化、医薬品開発、公衆衛生への取り組みに起因しています。

2型糖尿病市場規模は、今後数年間で力強い成長が見込まれます。2028年にはCAGR8.2％で658億9,000万米ドルに成長します。予測期間の成長は、世界の糖尿病の流行、個別化医療、技術の進歩、ヘルスケア政策の変更に起因すると考えられます。予測期間の主な動向には、デジタルヘルスと遠隔医療、予防と早期介入、人工知能（AI）と機械学習（ML）、代謝手術などが含まれます。

2型糖尿病市場の成長が期待される背景には、肥満と心臓病の割合の上昇があります。肥満は不健康なレベルまで過剰な体脂肪の蓄積を特徴とする病状であり、心臓病は心臓や血管に影響を及ぼすさまざまな状態を包含します。過剰な体重はインスリン抵抗性のリスクを高め、高血糖を引き起こし、2型糖尿病を発症させる。逆に、血糖値の上昇は、心臓や血管の機能を調節する血管や神経を障害し、最終的に心臓病を引き起こす可能性があります。例えば、2022年5月、米国の政府機関である疾病対策予防センターは、米国における重度の肥満が2021年には4.7％から9.2％に急増したと報告しました。さらに、英国の政府機関である国家統計局の2022年3月の報告では、心臓病による死亡者数が増加しており、2020年の19,440人から2021年には20,061人に増加しています。このように、肥満と心臓病の有病率の増加が2型糖尿病市場成長の原動力となっています。

2型糖尿病市場の成長には、老人人口の増加がさらに拍車をかけています。この層は65歳以上の高齢者で構成され、免疫力の低下や高齢のために様々な健康状態にかかりやすくなっています。加齢は、低血糖（低血糖）、腎不全、心臓病など、2型糖尿病に関連する問題のリスクを著しく高め、急性および慢性の微小血管および心血管合併症の両方に影響を与えます。2021年10月に世界保健機関（WHO）が発表したファクトシートでは、60歳以上の世界人口は2030年までに14億人に達し、2050年までにさらに21億人に増加すると予測されています。したがって、老人人口の増加は2型糖尿病市場の促進要因となっています。

2023年の2型糖尿病市場では北米が最大地域でした。欧州は予測期間で最も急成長する地域と予想されます。2型糖尿病レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の2型糖尿病市場、薬剤クラス別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • ジペプチジルペプチダーゼ-4（DPP-4）阻害剤
  • グルカゴン様ペプチド-1（GLP-1）受容体アゴニスト
  • チアゾリジンジオン
  • α-グルコシダーゼ阻害剤
  • スルホニルウレア剤およびその他のインスリン分泌促進薬
  • ビグアニデス
  • ナトリウムグルコース共輸送体2阻害剤
  • その他
  • 世界の2型糖尿病市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 血糖コントロール
  • 心臓血管の安全性
  • 低血糖の回避
  • その他
  • 世界の2型糖尿病市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 子供
  • 大人

第7章 地域および国の分析

  • 世界の2型糖尿病市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の2型糖尿病市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 2型糖尿病市場の競合情勢
  • 2型糖尿病市場の企業プロファイル
    • F. Hoffmann-La Roche AG
    • Merck and Co. Inc
    • Novartis AG
    • AstraZeneca plc
    • Abbott Laboratories

第31章 その他の主要および革新的な企業

  • Sanofi SA
  • Medtronic plc
  • Takeda Pharmaceutical Company
  • GlaxoSmithKline plc.
  • Eli Lilly and Company
  • Novo Nordisk A/S
  • Johnson And Johnson Private Limited
  • Daiichi Sankyo Co. Ltd
  • Boehringer Ingelheim International GmbH
  • Dexcom Inc
  • Amgen Inc.
  • Insulet Corporation
  • Ascensia Diabetes Care
  • Byram Healthcare
  • Beta Bionics

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r12396

“Type 2 Diabetes Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on type 2 diabetes market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for type 2 diabetes? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The type 2 diabetes market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Drug Class: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors; Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists; Thiazolidinediones; Alpha-Glucosidase Inhibitors; Sulfonylureas And Other Insulin Secretagogues; Biguanides; SodiumGlucose Cotransporter 2 Inhibitors; Other Drug Classes
  • 2) By Application: Glycemic Control; Cardiovascular Safety; Hypoglycemia Avoidance; Other Applications
  • 3) By End-User: Children; Adults
  • Companies Mentioned: F. Hoffmann-La Roche AG; Merck and Co. Inc; Novartis AG; AstraZeneca plc; Abbott Laboratories
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Type 2 diabetes is a persistent metabolic disorder characterized by elevated blood sugar levels attributed to insulin resistance and insufficient insulin production. The development of Type 2 diabetes is the result of a combination of genetic, lifestyle, and environmental factors. Effective management of type 2 diabetes can be achieved through dietary modifications, pharmaceutical interventions that aid in weight reduction, adherence to a healthy diet, and consistent physical activity.

In the realm of type 2 diabetes management, various classes of drugs are available, including dipeptidyl peptide-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, thiazolidinediones, alpha-glucosidase inhibitors, sulfonylureas, other insulin secretagogues, biguanides, sodium-glucose cotransporter 2 inhibitors, and others. Dipeptidyl peptidase-4 (DPP-4) inhibitors represent a class of oral medications designed to impede the action of the enzyme responsible for breaking down incretin hormones, which play a crucial role in regulating blood sugar levels. These drugs find applications in diverse areas, including glycemic control, cardiovascular safety, prevention of hypoglycemia, and more, catering to various age groups, including children and adults.

The type 2 diabetes market research report is one of a series of new reports from The Business Research Company that provides type 2 diabetes market statistics, including type 2 diabetes industry global market size, regional shares, competitors with a type 2 diabetes market share, detailed type 2 diabetes market segments, market trends and opportunities and any further data you may need to thrive in the type 2 diabetes industry. This type 2 diabetes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The type 2 diabetes market size has grown strongly in recent years. It will grow from $44.56 billion in 2023 to $48.14 billion in 2024 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to lifestyle and dietary changes, aging population, pharmaceutical developments, public health initiatives.

The type 2 diabetes market size is expected to see strong growth in the next few years. It will grow to $65.89 billion in 2028 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to global diabetes epidemic, personalized medicine, technological advancements, healthcare policy changes. Major trends in the forecast period include digital health and telemedicine, prevention and early intervention, artificial intelligence (AI) and machine learning (ML), metabolic surgery.

The anticipated growth of the type 2 diabetes market is attributed to the escalating rates of obesity and heart disease. Obesity is a medical condition characterized by the accumulation of excess body fat to unhealthy levels, while heart disease encompasses a range of conditions affecting the heart and blood vessels. Excess body weight elevates the risk of insulin resistance, resulting in high blood sugar levels and the onset of type 2 diabetes. Conversely, elevated blood sugar levels can lead to the impairment of blood vessels and nerves that regulate heart and vascular functions, ultimately causing heart disease. For example, in May 2022, the Centers for Disease Control and Prevention, a US-based government agency, reported that severe obesity in the US surged from 4.7% to 9.2% in 2021. Moreover, a March 2022 report from the UK's Office for National Statistics, a government department, indicated an increase in the number of deaths from heart disease, rising from 19,440 in 2020 to 20,061 in 2021. Thus, the increasing prevalence of obesity and heart disease is the driving force behind the growth of the type 2 diabetes market.

The growth of the type 2 diabetes market is further fueled by the increasing geriatric population. This demographic comprises older adults aged 65 and above, who are more susceptible to various health conditions due to their lowered immunity and advanced age. Aging significantly heightens the risk of problems associated with Type 2 diabetes, including issues like hypoglycemia (low blood sugar), renal failure, and heart disease, impacting both acute and chronic microvascular and cardiovascular complications. As an illustration, a factsheet published by the World Health Organization in October 2021 highlighted that the global population aged 60 and over is projected to reach 1.4 billion by 2030, with a further increase to 2.1 billion by 2050. Hence, the growing geriatric population serves as a driving factor for the type 2 diabetes market.

The growth of the type 2 diabetes market is hampered by the increasing cost of medications during the forecast period. The high expenses associated with diabetes medications create financial barriers for individuals dealing with Type 2 Diabetes, especially those lacking sufficient insurance coverage or facing substantial out-of-pocket costs. This can result in delayed or inadequate treatment, leading to poorly controlled blood sugar levels and heightened health risks. For instance, in June 2021, as reported by the National Library of Medicine, a US-based medical library, the average lifetime cost for all medications employed in diabetes treatment is estimated at $23,380.17. On average, the total monthly cost per patient stands at $1,521, with $11.94 allocated to medical expenses and $3.26 to non-medical expenditures. Consequently, the soaring medication costs are a hindrance to the growth of the type 2 diabetes market.

Prominent companies operating in the type 2 diabetes market are pioneering innovative products such as Mounjaro to elevate the standards of safety and effectiveness in diabetic patient care. Innovative medications like Mounjaro aim to enhance the efficiency, safety, or convenience of diabetes management when compared to existing drugs. Advancements in the development of diabetes treatments focus on optimizing blood sugar regulation, minimizing adverse effects, and addressing other associated health issues. For instance, in May 2022, Eli Lilly and Co., a US-based pharmaceutical firm, secured approval from the U.S. Food and Drug Administration, a US-based government body, for Mounjaro (tripeptide) injection as an adjunct to diet and exercise for improving blood sugar control in adults with type 2 diabetes. Tirzepatide, a novel, dual-targeted therapy for type 2 diabetes, is delivered as a once-weekly injection, simultaneously targeting two hormones involved in blood sugar regulation, namely glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). GLP-1 contributes to increased insulin production and reduced glucagon production, while GIP stimulates insulin production. Tirzepatide stands as a promising novel treatment option for individuals with type 2 diabetes, including those who have responded poorly to other treatments.

In July 2021, Eli Lilly and Company, a US-based pharmaceutical enterprise, completed the acquisition of Protomer Technologies Inc. for $1 billion. Through this acquisition, Eli Lilly aims to bolster its diabetes pipeline by integrating Protomer's glucose-sensing insulin program. This strategic move accelerates the development of innovative treatments for individuals grappling with this chronic condition, providing a more precise and effective treatment option for diabetes patients. Protomer Technologies Inc., based in the US, is a biotechnology company known for its development of PT-100, a small molecule intended for the treatment of type 2 diabetes.

Major players in the type 2 diabetes market are F. Hoffmann-La Roche AG, Merck and Co. Inc., Novartis AG, AstraZeneca PLC, Abbott Laboratories, Sanofi SA, Medtronic PLC, Takeda Pharmaceutical Company, GlaxoSmithKline plc., Eli Lilly and Company, Novo Nordisk A/S, Johnson And Johnson Private Limited, Daiichi Sankyo Co. Ltd., Boehringer Ingelheim International GmbH, Dexcom Inc., Amgen Inc., Insulet Corporation, Ascensia Diabetes Care, Byram Healthcare, Beta Bionics, Onduo LLC, DarioHealth, One Drop, Bigfoot Biomedical Inc., Digbi Health, MySugr GmbH, Senseonics Holdings Inc., Provention Bio Inc., Vida Health Inc., Diathrive Health .

North America was the largest region in the type 2 diabetes market in 2023. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in type 2 diabetes report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the type 2 diabetes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The type 2 diabetes market consists of revenues earned by entities by providing services such as blood sugar monitoring, diabetes education and support, bariatric surgery and lifestyle modifications. The market value includes the value of related goods sold by the service provider or included within the service offering. The type 2 diabetes market also includes sales of blood glucose meters, insulin pens, insulin syringes, insulin pumps, metformin and diabetic socks. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Type 2 Diabetes Market Characteristics

3. Type 2 Diabetes Market Trends And Strategies

4. Type 2 Diabetes Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Type 2 Diabetes Market Size and Growth

  • 5.1. Global Type 2 Diabetes Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Type 2 Diabetes Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Type 2 Diabetes Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Type 2 Diabetes Market Segmentation

  • 6.1. Global Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
  • Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
  • Thiazolidinediones
  • Alpha-Glucosidase Inhibitors
  • Sulfonylureas And Other Insulin Secretagogues
  • Biguanides
  • SodiumGlucose Cotransporter 2 Inhibitors
  • Other Drug Classes
  • 6.2. Global Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Glycemic Control
  • Cardiovascular Safety
  • Hypoglycemia Avoidance
  • Other Applications
  • 6.3. Global Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Children
  • Adults

7. Type 2 Diabetes Market Regional And Country Analysis

  • 7.1. Global Type 2 Diabetes Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Type 2 Diabetes Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Type 2 Diabetes Market

  • 8.1. Asia-Pacific Type 2 Diabetes Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Type 2 Diabetes Market

  • 9.1. China Type 2 Diabetes Market Overview
  • 9.2. China Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Type 2 Diabetes Market

  • 10.1. India Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Type 2 Diabetes Market

  • 11.1. Japan Type 2 Diabetes Market Overview
  • 11.2. Japan Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Type 2 Diabetes Market

  • 12.1. Australia Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Type 2 Diabetes Market

  • 13.1. Indonesia Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Type 2 Diabetes Market

  • 14.1. South Korea Type 2 Diabetes Market Overview
  • 14.2. South Korea Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Type 2 Diabetes Market

  • 15.1. Western Europe Type 2 Diabetes Market Overview
  • 15.2. Western Europe Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Type 2 Diabetes Market

  • 16.1. UK Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Type 2 Diabetes Market

  • 17.1. Germany Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Type 2 Diabetes Market

  • 18.1. France Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Type 2 Diabetes Market

  • 19.1. Italy Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Type 2 Diabetes Market

  • 20.1. Spain Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Type 2 Diabetes Market

  • 21.1. Eastern Europe Type 2 Diabetes Market Overview
  • 21.2. Eastern Europe Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Type 2 Diabetes Market

  • 22.1. Russia Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Type 2 Diabetes Market

  • 23.1. North America Type 2 Diabetes Market Overview
  • 23.2. North America Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Type 2 Diabetes Market

  • 24.1. USA Type 2 Diabetes Market Overview
  • 24.2. USA Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Type 2 Diabetes Market

  • 25.1. Canada Type 2 Diabetes Market Overview
  • 25.2. Canada Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Type 2 Diabetes Market

  • 26.1. South America Type 2 Diabetes Market Overview
  • 26.2. South America Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Type 2 Diabetes Market

  • 27.1. Brazil Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Type 2 Diabetes Market

  • 28.1. Middle East Type 2 Diabetes Market Overview
  • 28.2. Middle East Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Type 2 Diabetes Market

  • 29.1. Africa Type 2 Diabetes Market Overview
  • 29.2. Africa Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Type 2 Diabetes Market Competitive Landscape And Company Profiles

  • 30.1. Type 2 Diabetes Market Competitive Landscape
  • 30.2. Type 2 Diabetes Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche AG
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Merck and Co. Inc
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Novartis AG
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. AstraZeneca plc
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Abbott Laboratories
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Type 2 Diabetes Market Other Major And Innovative Companies

  • 31.1. Sanofi SA
  • 31.2. Medtronic plc
  • 31.3. Takeda Pharmaceutical Company
  • 31.4. GlaxoSmithKline plc.
  • 31.5. Eli Lilly and Company
  • 31.6. Novo Nordisk A/S
  • 31.7. Johnson And Johnson Private Limited
  • 31.8. Daiichi Sankyo Co. Ltd
  • 31.9. Boehringer Ingelheim International GmbH
  • 31.10. Dexcom Inc
  • 31.11. Amgen Inc.
  • 31.12. Insulet Corporation
  • 31.13. Ascensia Diabetes Care
  • 31.14. Byram Healthcare
  • 31.15. Beta Bionics

32. Global Type 2 Diabetes Market Competitive Benchmarking

33. Global Type 2 Diabetes Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Type 2 Diabetes Market

35. Type 2 Diabetes Market Future Outlook and Potential Analysis

  • 35.1 Type 2 Diabetes Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Type 2 Diabetes Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Type 2 Diabetes Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer